{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:42:51Z","timestamp":1792428171918,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"DOI":"10.1007\/s11606-026-10874-w","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:18:02Z","timestamp":1792426682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progressive Multifocal Leukoencephalopathy Arising in HIV-Negative Idiopathic CD4+ Lymphocytopenia: A Multidisciplinary Case"],"prefix":"10.1007","author":[{"given":"Madeleine","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina J.","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Malvestutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6536-1169","authenticated-orcid":false,"given":"Kaitlyn","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"10874_CR1","doi-asserted-by":"publisher","unstructured":"Varmpompiti K, Westwood A, Ben-Joseph A, et al. Progressive multifocal leukoencephalopathy secondary to idiopathic CD4 lymphocytopenia treated with pembrolizumab. J Neuroimmunol. 2023;385:578248. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578248.","DOI":"10.1016\/j.jneuroim.2023.578248"},{"key":"10874_CR2","doi-asserted-by":"publisher","unstructured":"Haider S, Nafziger D, Gutierrez JA, Brar I, Mateo N, and Fogle J. Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: a case report and review of reported cases. Clin Infect Dis. 2000;31(4):E20-22. https:\/\/doi.org\/10.1086\/318120.","DOI":"10.1086\/318120"},{"key":"10874_CR3","doi-asserted-by":"publisher","unstructured":"Zonios D, Sheikh V, and Sereti I. Idiopathic CD4 lymphocytopenia: a case of missing, wandering or ineffective T cells. Arthritis Res Ther. 2012;14(4):222. https:\/\/doi.org\/10.1186\/ar4027.","DOI":"10.1186\/ar4027"},{"key":"10874_CR4","doi-asserted-by":"publisher","unstructured":"Boumaza X, Bonnaeu B, Roos-Weil D, et al. Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors. Ann Neurol. 2023;93(2):257-270. https:\/\/doi.org\/10.1002\/ana.26512.","DOI":"10.1002\/ana.26512"},{"key":"10874_CR5","doi-asserted-by":"publisher","unstructured":"Aotsuka Y, Uzawa A, Nishimura K, et al. Progressive multifocal leukoencephalopathy localized in the cerebellum and brainstem associated with idiopathic CD4(+) T lymphocytopenia. Intern Med. 2016;55(12):1645-1647. https:\/\/doi.org\/10.2169\/internalmedicine.55.6649.","DOI":"10.2169\/internalmedicine.55.6649"},{"key":"10874_CR6","doi-asserted-by":"publisher","unstructured":"Dato C, Elefante A, Coppola C, et al. \u201cBorderline\u201d idiopathic CD4(+) T-cell lymphocytopenia presenting with atypical progressive multifocal leukoencephalopathy. J Neuroimmunol. 2020;349:577420. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577420","DOI":"10.1016\/j.jneuroim.2020.577420"},{"key":"10874_CR7","doi-asserted-by":"publisher","unstructured":"Delgado-Alvarado M, Sedano MJ, Gonzalez-Quintanilla V, Marco de Lucas E, Polo JM, Berciano J. Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia. J Neurol Sci. 2013;327(1\u20132):75\u201379. https:\/\/doi.org\/10.1016\/j.jns.2013.02.002.","DOI":"10.1016\/j.jns.2013.02.002"},{"key":"10874_CR8","doi-asserted-by":"publisher","unstructured":"Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry. 2010;81(3)247-254. https:\/\/doi.org\/10.1136\/jnnp.2009.187666.","DOI":"10.1136\/jnnp.2009.187666"},{"key":"10874_CR9","doi-asserted-by":"publisher","unstructured":"Nambirajan A, Suri V, Kataria V, Sharma M, Goyal V. Progressive multifocal leukoencephalopathy in a 44-year old male with idiopathic CD4+ T-lymphocytopenia treated with mirtazapine and mefloquine. Neurol India. 2017;65(5):1061-1064. https:\/\/doi.org\/10.4103\/neuroindia.NI_535_16.","DOI":"10.4103\/neuroindia.NI_535_16"},{"key":"10874_CR10","doi-asserted-by":"publisher","unstructured":"Moln\u00e1r, E, Radwan, N, Kov\u00e1cs, G et al. Key diagnostic markers for autoimmune lymphoproliferative syndrome with molecular genetic diagnosis.\u00a0Blood. 2020;136(17):1933-1945. https:\/\/doi.org\/10.1182\/blood.2020005486.","DOI":"10.1182\/blood.2020005486"},{"key":"10874_CR11","unstructured":"National Institute of Neurological Disorders and Stroke. Progressive multifocal leukoencephalopathy. Updated March 12, 2026. Accessed March 28, 2026. https:\/\/www.ninds.nih.gov\/health-information\/disorders\/progressive-multifocal-leukoencephalopathy."},{"key":"10874_CR12","doi-asserted-by":"publisher","unstructured":"Mori K, Kurokawa M, Harada M, et al. Overview of MRI findings in progressive multifocal leukoencephalopathy. Jpn J Radiol. 2025;43(12):1908-25. https:\/\/doi.org\/10.1007\/s11604-025-01837-y.","DOI":"10.1007\/s11604-025-01837-y"},{"key":"10874_CR13","doi-asserted-by":"publisher","unstructured":"Berger JR, Askamit AJ, Clifford DB, et al. PML diagnostic criteria. Neurology. 2013;80(15):1430-1438. https:\/\/doi.org\/10.1212\/WNL.0b013e31828c2fa1.","DOI":"10.1212\/WNL.0b013e31828c2fa1"},{"key":"10874_CR14","doi-asserted-by":"publisher","unstructured":"Jia DT. Progressive multifocal leukoencephalopathy \u2014 a diagnostic guide for the clinical neurologist. Front Neurol. 2026;17:1692522. https:\/\/doi.org\/10.3389\/fneur.2026.1692522.","DOI":"10.3389\/fneur.2026.1692522"},{"key":"10874_CR15","doi-asserted-by":"publisher","unstructured":"Weber T. Progressive multifocal leukoencephalopathy. Neurol Clin. 2008;26(3):833-854. https:\/\/doi.org\/10.1016\/j.ncl.2008.03.007.","DOI":"10.1016\/j.ncl.2008.03.007"},{"key":"10874_CR16","doi-asserted-by":"publisher","unstructured":"Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199(1):77-83. https:\/\/doi.org\/10.1086\/595299.","DOI":"10.1086\/595299"},{"key":"10874_CR17","doi-asserted-by":"publisher","unstructured":"Aye SL, Trivedi Y, Bolgarina Z, et al. The prognosis of progressive multifocal leukoencephalopathy in HIV\/AIDS patients undergoing highly active antiretroviral treatment: a systematic review. Cureus. 2023;15(9):e45155. https:\/\/doi.org\/10.7759\/cureus.45155.","DOI":"10.7759\/cureus.45155"},{"key":"10874_CR18","doi-asserted-by":"publisher","unstructured":"Ho DD, Cao Y, Zhu T, Farthing C, Wang N, Gu G, Schooley RT, Daar ES. Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection. N Engl J Med. 1993;328(6):380-5. https:\/\/doi.org\/10.1056\/NEJM199302113280602.","DOI":"10.1056\/NEJM199302113280602"},{"key":"10874_CR19","doi-asserted-by":"publisher","unstructured":"Fauci AS. CD4+ T-lymphocytopenia without HIV infection--no lights, no camera, just facts. N Engl J Med. 1993;328(6):429-31. https:\/\/doi.org\/10.1056\/NEJM199302113280610.","DOI":"10.1056\/NEJM199302113280610"},{"key":"10874_CR20","doi-asserted-by":"publisher","unstructured":"Zonios DI, Falloon J, Bennett JE, Shaw PA, Chaitt D, Baseler MW, Adelsberger JW, Metcalf JA, Polis MA, Kovacs SJ, Kovacs JA. Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood. 2008;112(2):287-94. https:\/\/doi.org\/10.1182\/blood-2007-12-127878.","DOI":"10.1182\/blood-2007-12-127878"},{"key":"10874_CR21","doi-asserted-by":"publisher","unstructured":"Brooks JP and Ghaffari G. Idiopathic CD4 lymphocytopenia. Allergy Asthma Proc. 2016;37(6):501-504. https:\/\/doi.org\/10.2500\/aap.2016.37.3992.","DOI":"10.2500\/aap.2016.37.3992"},{"key":"10874_CR22","doi-asserted-by":"publisher","unstructured":"Lisco A, Freeman AF, Sereti I. Idiopathic CD4 lymphopenia. In: Sullivan KE, Stiehm ER, editors. Stiehm\u2019s immune deficiencies: inborn errors of immunity. 2nd ed. London: Academic Press; 2020. p. 381\u201392. https:\/\/doi.org\/10.1016\/B978-0-12-816768-7.00014-4.","DOI":"10.1016\/B978-0-12-816768-7.00014-4"},{"key":"10874_CR23","doi-asserted-by":"publisher","unstructured":"Lisco A, Ortega-Villa AM, Mystakelis H, Anderson MV, Mateja A, Laidlaw E, Manion M, Roby G, Higgins J, Kuriakose S, Walkiewicz MA. Reappraisal of idiopathic CD4 lymphocytopenia at 30 years. New England Journal of Medicine. 2023 May 4;388(18):1680-91. https:\/\/doi.org\/10.1056\/NEJMoa2202348.","DOI":"10.1056\/NEJMoa2202348"},{"key":"10874_CR24","doi-asserted-by":"publisher","unstructured":"Nazneen KS, Mascarenhas N, Elsheikh E, Rezwanuzzaman SM, Kumar S. A case report of progressive multifocal leukoencephalopathy (PML) in an immunocompetent patient. Cureus. 2025;17(9):e91491. https:\/\/doi.org\/10.7759\/cureus.91491.","DOI":"10.7759\/cureus.91491"},{"key":"10874_CR25","doi-asserted-by":"publisher","unstructured":"Tan CS and Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9(4):425-437. https:\/\/doi.org\/10.1016\/S1474-4422(10)70040-5.","DOI":"10.1016\/S1474-4422(10)70040-5"},{"key":"10874_CR26","doi-asserted-by":"publisher","unstructured":"Rubinstein JD, Jodele S, Heyenbruch D, et al. Off-the-shelf third-party virus-specific T cell therapy to treat JC polyomavirus infection in hematopoietic stem cell transplantation recipients. Transplant Cell Ther. 2022;28(2):116.e1-116.e7. https:\/\/doi.org\/10.1016\/j.jtct.2021.11.005.","DOI":"10.1016\/j.jtct.2021.11.005"},{"key":"10874_CR27","doi-asserted-by":"publisher","unstructured":"Joly M, Conte C, Cazanave C, et al. Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions. Brain. 2023;146(1)349-358. https:\/\/doi.org\/10.1093\/brain\/awac237.","DOI":"10.1093\/brain\/awac237"},{"key":"10874_CR28","doi-asserted-by":"publisher","unstructured":"Anand P, Hotan GC, Vogel A, Venna N, Mateen F. Progressive multifocal leukoencephalopathy: a 25-year retrospective cohort study. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e618. https:\/\/doi.org\/10.1212\/NXI.0000000000000618.","DOI":"10.1212\/NXI.0000000000000618"},{"key":"10874_CR29","doi-asserted-by":"publisher","unstructured":"Berzero G, Basso S, Stoppini L, et al. Adoptive transfer of JC virus-specific T lymphocytes for the treatment of progressive multifocal leukoencephalopathy. Ann Neurol. 2021;89(4):769-779. https:\/\/doi.org\/10.1002\/ana.26020.","DOI":"10.1002\/ana.26020"},{"key":"10874_CR30","doi-asserted-by":"publisher","unstructured":"Pocora MM, Bini P, Berzero G, et al. Adoptive JC virus-specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy: Experience from Two Italian Centers. Viruses. 2025;17(7):934. https:\/\/doi.org\/10.3390\/v17070934.","DOI":"10.3390\/v17070934"},{"key":"10874_CR31","doi-asserted-by":"publisher","unstructured":"Walter O, Treiner E, Bonneville F, et al. Treatment of progressive multifocal leukoencephalopathy with nivolumab. N Engl J Med. 2019;380(17):1674-1676. https:\/\/doi.org\/10.1056\/NEJMc1816198.","DOI":"10.1056\/NEJMc1816198"},{"key":"10874_CR32","doi-asserted-by":"publisher","unstructured":"M\u00f6hn N, Grote-Levi L, Bonifacious A, et al. Virus-specific T cells and response to checkpoint inhibitors in progressive multifocal leukoencephalopathy. JAMA Neurol. 2026;83(3):280-289. https:\/\/doi.org\/10.1001\/jamaneurol.2025.5318.","DOI":"10.1001\/jamaneurol.2025.5318"},{"key":"10874_CR33","doi-asserted-by":"publisher","unstructured":"Rauer S, Marks R, Urbach H, et al. Treatment of progressive multifocal leukoencephalopathy with pembrolizumab. N Engl J Med. 2019;380(17):1676-1677. https:\/\/doi.org\/10.1056\/NEJMc1817193.","DOI":"10.1056\/NEJMc1817193"},{"key":"10874_CR34","doi-asserted-by":"publisher","unstructured":"Cortese I, Muranski P, Enose-Akhata Y, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med. 2019;380(17):1597-1605. https:\/\/doi.org\/10.1056\/NEJMoa1815039.","DOI":"10.1056\/NEJMoa1815039"},{"key":"10874_CR35","doi-asserted-by":"publisher","unstructured":"Yin Q, Wu L, Han L, et al. Immune-related adverse events immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975. https:\/\/doi.org\/10.3389\/fimmu.2023.1167975.","DOI":"10.3389\/fimmu.2023.1167975"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10874-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10874-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10874-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:18:04Z","timestamp":1792426684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10874-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":35,"alternative-id":["10874"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10874-w","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KG, MD, CJD, CAH, and CB declare no competing interests. CM reports grants and personal fees from Gilead Sciences Inc., personal fees from HealthHIV, and grants and personal fees from Viiv Healthcare, outside the submitted work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}